Trevor Mundel, Novartis' global head of development, says that the findings ???reinforce the potential for Gilenia to be a breakthrough therapy option for physicians and people with relapsing forms of MS??? and that they ???demonstrate the effectiveness of Gilenia irrespective of treatment history??? and ???the potential benefits of switching from interferon beta-1a, a currently approved MS therap